National Account Executive
CurrentAppointed by executive management to serve as an integral member of a joint venture team with Schering-Plough, which encompassed managing, negotiating direct contracts, rebates, and reimbursement, and attaining positive formulary status for Vytorin and Zetia at national accounts, including Medco and State Medicaid accounts in Connecticut and Rhode Island. Collaborate with team to devise and implement pull-through programs for utilization at the field level. Form strategic relationships throughout organizations to drive formulary access and market share, including Chief Medical Officers, Pharmacy Directors, Contracting Vice Presidents, Legal, and Drug Distribution and Control personnel. Selected accomplishments: • Generated $550 million in gross sales for Vytorin and Zetia at Medco by consistently achieving preferred formulary status despite market events. • Achieved up to 11% market share for Vytorin and 8% for Zetia in commercial accounts, and 7.3% for Vytorin and 8% for Zetia within Medicaid providers.• Developed and garnered approval from executives and board of directors for implementation of an Advancing Quality pull-through program for utilization with Medco, designed to address patient compliance and persistency, ensure physician currency with guidelines, support quality initiatives, augment activities, and adjudicate claims.• Collaborated with field sales to identify and devise pull-through programs for employers in different states utilizing Medco, which is projected to increase market share to 5.9% versus national average of 4.8%. • Attained Preferred Drug List (PDL) status for Vytorin and Zetia on Connecticut and Rhode Island State Medicaid.• Partnered with Government Affairs to circumvent a Marketing / Disclosure bill introduced in the State of Connecticut authored to limit pharmaceutical representatives access and discussion topics, which encompassed identifying / meeting with #1 advocate Senator and resulted in defeating the legislation.